|
32. Ulug S, Riley EP. The effect of
methylphenidate on overactivity in rats prenatally exposed to alcohol.
Neurobehav Toxicol Teratol 1983;5:35–9.
33. Means LW, Medlin CW, Hughes VD, Gray SL. Rats
exposed in utero to ethanol are hyperresponsive to methylphenidate
when tested as neonates or adults. Neurobehav Toxicol Teratol 1984;6:18.
34. O’Malley KD. Medication therapy’s
role for FAS. Iceberg 1997;7:1,3–4.
35. Coles CD, Platzman KA, Raskind-Hood CL, Brown
RT, Falek A, Smith IE. A comparison of children affected by prenatal
alcohol exposure and attention deficit hyperactivity disorder. Alcohol
Clin Exp Res 1997;1:150–61.
36. Weinberg NZ. Cognitive and behavioral deficits
associated with parental alcohol use. J Am Acad Child Adolesc Psychiatry
1997;36:1177–86.
37. Oesterheld J, O’Malley KD. Are ADHD and
FAS really that similar? Iceberg 1999;9,:1,7.
38. O’Malley KD. Fetal alcohol effect and ADHD
J Am Acad Child Adolesc Psychiatry 1994;33:1059–60.
39. Rutter M. Brain damage syndromes in childhood:
concepts and findings. J Child Psychol Psychiatry 1977;18:1–21.
40. Biederman J, Newcorn J, Sprich S. Co-morbidity
of attention deficit hyperactivity disorder with conduct, depression,
anxiety and other disorders. Am J Psychiatry 1991;148:564.
41. Milberger S, Biederman J, Farone SV, Murphy
J, Tsuang MT. Attention deficit hyperactivity disorders: issues
of overlapping syndromes. Am J Psychiatry 1995;152:1793–9.
42. Lahoste G, Swanson JM, Wigal SB. Dopamine D4
receptor gene polymorphism is associated with attention deficit
hyperactivity disorder. Mol Psychiatry 1996:121–4.
43. Cyr M, Brown CS. Current drug therapy recommendations
for the treatment of ADHD. Drug 1998;56:215–22.
44. Pliszka SR, McCracken JT, Maas JW. Catecholamines
in attention deficit hyperactivity disorder current perspectives.
J Am Acad Child Adolesc Psychiatry 1996;35:264–72.
45. Castellanos FX. Toward a pathophysiology of
attention deficit/hyperactivity disorder. Clin Paediatr 1997;3:381–93.
46. Druse MJ. Effects of maternal alcohol consumption
on the developing nervous system. In: Watson RR, editor. Alcohol
and neurobiology: brain development and hormone regulation. Boca
Raton: CRC Press; 1992.
47. Manteuffel MD. Neurotransmitter function: changes
associated with in utero alcohol exposure. In: Abel EL, editor.
Fetal alcohol syndrome: from mechanism to prevention. New York:
CRC Press; 1996. p 171–89.
48. Ferrer I, Galofre E. Dendritic spine anomalies
in fetal alcohol syndrome. Neuropediatrics 1987;18:161–3.
49. Miller MW, Chiaia NL, Rhoades RW. Intracellular
recording and injection study of corticospinal neurons in the rat
somatosensory cortex: effect of prenatal exposure to ethanol. J
Comp Neurol 1990;297:91–105.
50. Gillespie RA, Eriksen J, Hao HL, Druse MJ. Effects
of maternal ethanol consumption and buspirone treatment on dopamine
and norepinephrine reuptake sites and D1 receptors in offspring.
Alcohol Clin Exp Res 1997;21:452–8.
51. Abel EL. Fetal alcohol syndrome and fetal alcohol
effects. New York: Plenum Press; 1984.
52. Driscoll CD, Streissguth AP, Riley EP. Prenatal
alcohol exposure: comparability of effects in humans and animal
models, Neurotoxicol Teratol 1990;12:231–7.
53. Streissguth AP, Clarren SK, Jones KL. Natural
history of the fetal alcohol syndrome: a 10-year follow-up of eleven
patients. Lancet 1985;85–91.
54. Connor PD, Sampson PD, Bookstein FL, Barr HM,
Streissguth AP Direct and indirect effects of prenatal alcohol damage
on executive function. Dev Neuropsychol 2000;18:331–54.
55. Barr HM, Streissguth AP, Darby BL, Sampson PD.
Prenatal exposure to alcohol, caffeine, tobacco and aspirin: effects
on fine motor and gross motor performance in 4 year old children.
Dev Psychol 1990;26:339–48.
56. Hannigan, JH, Pilati ML. The effects of chronic
postweaning amphetamine on rats exposed to alcohol in utero: weight
gain and behavior. Neurotoxicol Teratol 1991;13:649–56.
57. Riley, EP. The long-term behavioral effects
of prenatal alcohol exposure in rats. Alcohol Clini Exp Res 1990;14:670–3.
58. Sulik KK, Johnston MC, Webb MA. Fetal alcohol
syndrome: embryogenesis in a mouse model. Science 1981;214:936–8.
59. Mirsky AF, Anthony BJ, Duncan CC, Ahern MB,
Kellam SG. Analysis of the elements of atttention: a neuropsychological
approach. Neuropsychol Rev 1991;2:75–88.
60. Coles CD. Going beyond ADHD to understand behavior
and learning problems in FAS. Iceberg 1998;8:1–2.
61. Coggins TE, Friet T, Morgan T. Analyzing narrative
productions in older school-age children and adolescents with fetal
alcohol syndrome; an experimental tool for clinical applications,
Clinical Linguistics and Phonetics 1998;12:221–36.
62. Aman MG, Kern RA, McGhee DE, Arnold LE. Fenfluramine
and methylphenidate in children with mental retardation and ADHD:
clinical and side effects. J Am Acad Child Adolesc Psychiatry 1993;32:851–9.
|
|
63. Aman, MG, Kern RA, McGhee DE, Arnold LE. Fenfluramine
and methylphenidate in children with mental retardation and ADHD:
laboratory effects. J Autism Develop Disord 1993;23:491–506.
64. Gadow KD, Pomeroy JC, Nolan EE. A procedure
for monitoring stimulant medication in hyperactive mentally retarded
school children. J Child Adolesc Psychopharmacol 1992;2:131–43.
65. Handen BL, Breaux AM, Gosling A, Ploof DL, Feldman
H. Efficacy of methylphenidate among mentally retarded children
with attention deficit hyperactivity disorder. Pediatr 1990;86:922–30.
66. Handen BL, Breaux AM, Janosky J, McAuliffe S,
Feldman H, Gosling A. Effects and noneffects of methylphenidate
in children with mental retardation and ADHD. J Am Acad Child Adolesc
Psychiatry 1992;31:455–61.
67. Mayes SD, Crites DL, Bixler EO, Humphrey FJ,
Mattison RE. Methylphenidate and ADHD: influence of age, IQ and
neurodevelopmental status. Dev Med Child Neurol 1994;36:1099–1101.
68. Aman MG, Marks RE, Turbott SH, Wilsher CP, Merry
SN. Methylphenidate and thioridazine in the treatment of intellectually
sub average children: effects on cognitive-motor performance. J
Am Acad Child Adolesc Psychiatry 1991;30:816–24.
69. Coe JA, Sidders J, Riley K, Waltermire J, Hagerman
RJ. A survey of medication responses in children and adolescents
with fetal alcohol syndrome. J Dev Behav Pediatr. Forthcoming.
70. O’Malley KD, Koplin B, Dohner VA. Psychostimulant
response in fetal alcohol syndrome. Can J Psychiatry 2000;45:90–1.
71. Oesterheld JR, Kofoed L, Tervo R, Fogas B, Wilson
A, Fiechtner H. Effectiveness of methylphenidate in native american
children with fetal alcohol syndrome and attention deficit/hyperactivity
disorder: a controlled pilot study. J Child Adolesc Psychopharmacol
1998;8:39–48.
72. Snyder J, Nanson J, Snyder, RE, Block GW. Stimulant
efficacy in children with FAS. In: Streissguth A, Kanter J, editors.
The challenge of fetal alcohol syndrome: overcoming secondary disabilities.
Seattle (WA): University of Washington Press; 1997. p 64–77.
73. Hales RE, Yudofsky SC. Synopsis of psychiatry
2nd ed. Washington (DC):American Psychiatric Press; 1994. p 1127–67,
837–946.
74. Reiss S, Aman MG. Psychotropic medication and
developmental disabilities: In: The international consensus handbook.
Reiss S, Aman MG, editors, Columbus (OH): The Ohio State University
Nisonger Center; 1998.
75. O’Malley KD, Huffine C. Family-centred
multisystem and multimodal treatment approach to fetal alcohol spectrum
disorders. Considerations for community psychiatrists. Community
Mental Health Journal 2002. Forthcoming.
76. Sprenger DL, Josephson AM. Integration of pharmacotherapy
and family therapy in the treatment of children and adolescents.
J Am Acad Child Adolesc Psychiatry 1998;37:887–9.
77. American Academy of Pediatrics, Subcommittee
on Attention- Deficit/Hyperactivity Disorder, Committee on Quality
Improvement. Clinical practice guideline: treatment of the school-aged
child with attention-deficit/hyperactivity disorder. Pediatrics
2001;108:1033–44.
78. The MTA Co-Operative Group. Moderators and mediators
of treatment response for children with ADHD: the multi-modal treatment
study of children with ADHD. Arch Gen Psychiatry 1999;56:1088–96.
79. Van Groll BJ, Appel JB. Stimulant effects of
d-amphetamine 1; DA mechanisms. Pharmacol Biochem Behav 1992;43:967–73.
80. Volkow ND, Fowler JS, Ding YS, Wang GJ, Gatley
SJ. Adv Pharmacol 1998;42:211–4.
81. Lou HC, Henriksen L, Bruhn P, Borner H, Nielsen
JB. Striatal dysfunction in attention deficit and hyperkinetic disorder.
Arch Neurol 1989;46:48–52.
82. Volkow N, Wang GJ, Fowler JL, Angrist B, Hitzemann
R, Lieberman J, Pappas N. Effects of methylphenidate on regional
brain glucose metabolism in humans: relationship to dopamine D2
receptors. Am J Psychiatry 1997;154:50–5.
83. Rapoport JL. The development of neurodevelopmental
psychiatry. Am J Psychiatry 2000;157:159–61.
84. Institute of Medicine. Fetal alcohol syndrome:
diagnosis, epidemiology, prevention, and treatment. Washington (DC):
National Academy Press: 1996.
------------------------------------------------
Manuscript received May 2001, revised, and
accepted February 2002.
1 Formerly, Psychiatric Consultant, Edmonton FAS clinic,
Glenrose Hospital, Edmonton, Alberta; now, Acting Assistant Professor,
Department of Psychiatry and Behavioral Sciences, Fetal Alcohol
and Drug Unit and Henry M Jackson School of International Studies,
University of Washington, Seattle, Washington.
2 Associate Professor, Department of Psychology, University
of Saskatoon, Saskatoon, Saskatchewan.
Address for correspondence: Dr KD O’Malley, University
of Washington, Department of Psychiatry and Behavioral Sciences,
Fetal Alcohol and Drug Unit, Suite 309, 180 Nickerson Street, Seattle,
WA 98109
e mail: kieranom
@u.washington.edu
|
